News
November 14, 2017
Toronto, November 14, 2017 – Brand-name drug companies’ research and development spending as a percentage of sales in Canada is less than half of the 10% the industry committed to when their periods of market exclusivity were increased in 1987, according to the most recent annual report from the federal government’s Patented Medicine Prices Review Board (PMPRB).
October 2, 2017
Toronto, October 2, 2017 – The Canadian Generic Pharmaceutical Association (CGPA) is pleased to announce the election of Mr. Doug Sommerville, Senior Vice President and General Manager of Teva Canada, as Chair of CGPA, and, Jean-Guy Goulet, Chief Operating Officer of Pharmascience as Vice Chair of CGPA.
September 22, 2017
North American Generic and Biosimilar Medicines Industries Release Priorities for Renegotiation of NAFTA